Fig 1



+ Censored
Probability of cGVHD mild
1.0
0.8
0.6
0.4
0.2
0.0
KRP203 1mg + CsA 1 5 5 4 3 2 1 1 1 1 1 1 0
KRP203 3mg + Tac 2 3 3 3 2 2 1 1 0
KRP203 3mg + CsA 3 8 8 8 8 8 8 7 7 7 7 7 7 6 1 0
0
200
400
600
800
Time (days)
KRP203 1mg + CsA
KRP203 3mg + Tac
KRP203 3mg + CsA

Fig 2



+ Censored
Probability of relapse
1.0
0.8
0.6
0.4
0.2
0.0
KRP203 1mg + CsA 1 6 6 5 5 4 2 2 2 2 2 2 1 0
KRP203 3mg + Tac 2 6 4 3 2 2 2 2 1 1 1 0
KRP203 3mg + CsA 3 10 10 10 10 10 9 8 8 8 8 8 8 7 1 0
0
200
400
600
800
Times (days)
KRP203 1mg + CsA
KRP203 3mg + Tac
KRP203 3mg + CsA

Fig 3



+ Censored
Probability of cGVHD moderate
1.0
0.8
0.6
0.4
0.2
0.0
KRP203 1mg + CsA 1 6 6 3 3 2 1 1 1 1 1 1 1 0
KRP203 3mg + Tac 2 4 4 3 2 2 2 1 1 1 1 0
KRP203 3mg + CsA 3 9 9 9 7 6 6 5 2 2 2 2 2 1 0
0
200
400
600
800
Times (days)
KRP203 1mg + CsA
KRP203 3mg + Tac
KRP203 3mg + CsA

Fig 4A



Skin clinical score
score
4
3
2
1
0
0
10
20
30
40
50
days
KRP
Vechicle

Fig 4B



schilmar test(day42)
10
8
6
4
2
0
mm
KRP
Vehicle
KRP
Vehicle

Fig 5A




Survival proportions: Survival of OS
Probability of Survival
100
50
0
0
20
40
days after SCT
KRP203 + CsA short-term
KRP203 + CsA long-term
KRP203
placebo
TCDBM only (no GVHD)

Fig 5B


tumor count
6×10^6
5×10^6
4×10^6
3×10^6
2×10^6
1.5×10^6
1.0×10^6
5.0×10^5
0.0
tumor count
0
7
14
21
28
35
42
days after SCT
KRP203 + CsA short-term
KRP203 + CsA long-term
KRP203
placebo
TCDBM only (no GVHD)